{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 28,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to explain the scientific basis and product profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/23",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.86,
        "x": 0.07,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Regulatory approval received in New Zealand to advance AB-101 into a Phase 1 clinical trial; dosing expected to begin Q3 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b575f2c-1100-4c80-ae7b-acc4792c8281",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.36,
        "y": 0.23
      },
      "kind": "list",
      "text": "Small-Molecule Inhibitor Approach: Allows controlled checkpoint blockade; Enables oral dosing; Designed to reduce systemic safety issues seen with Abs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14cb09b1-4e65-4f01-936f-1f0980586af5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "Rationale: HBV immune tolerance is a critical driver of cHBV infection; PD-1:PD-L1 checkpoint axis plays a key role; PD-L1 expression upregulated; PD-1 upregulated; Inhibition associated with HBsAg loss.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aee51710-7a30-4d43-b135-31c9e13b3fbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "list",
      "text": "AB-101: Blocks PD-L1/PD-1 interaction; Activates HBV-specific immune responses; Novel MOA identified; Demonstrates robust checkpoint mediated in vivo effect; Improves HBV-specific T- and B-cell responses.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8cd6675-f430-435e-a2a3-ba5ac98d6e61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9205e73-5223-447d-ad08-ca5f4b9d0da6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}